i-SENS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
i-SENS - overview
Established
2000
Location
Seoul, -, South Korea
Primary Industry
Medical Devices & Equipment
About
Based in Seoul, South Korea. and founded in 2000, i-SENS specializes in glucose monitoring technology. The company has focused consistently on developing blood glucose monitoring systems and continuous glucose monitoring devices. In April 2024, ANDA Asset Management, Atinum Investment, and Korea Investment Partners acquired convertible bonds in i-SENS at KRW 19,279 apiece for KRW 50 billion, in a PIPE transaction.
The company's CEO is Hakhyun Nam, who has contributed significantly to its strategic direction. i-SENS, Inc. specializes in the development and manufacturing of advanced glucose monitoring solutions, particularly focusing on blood glucose monitoring systems and continuous glucose monitoring (CGM) devices. Their flagship products, including the CareSens line of glucose meters and the CareSens Air application, facilitate real-time glucose management and data sharing for individuals with diabetes.
The CareSens Air app allows users to view their glucose trends and set alerts to achieve target management levels. i-SENS primarily targets healthcare providers, diabetes patients, and caregivers, contributing to improved health outcomes through enhanced monitoring capabilities. The company's products are marketed globally, with significant distribution in North America, Europe, and parts of Asia, catering to a diverse clientele that includes both healthcare professionals and individual consumers. The company generates revenue primarily through the sale of its glucose monitoring devices and associated services.
The company engages in partnerships with healthcare providers and retailers to ensure broad market accessibility. In 2023, the revenue amounted to KRW 203,083,572. 2, with an EBITDA of KRW 18,763,391. Typical transactions involve the sale of glucose meters and subscription-based access to the CareSens Air app, providing users comprehensive data analysis and support tools, reflecting the company's commitment to innovative solutions that empower diabetes management.
Looking ahead, i-SENS aims to launch new products focused on enhancing glucose monitoring functionalities, with specific designs underway expected to be released in the upcoming year. The company plans to expand its presence in new markets, particularly targeting regions in Southeast Asia and Europe by 2025. The recent PIPE funding round, which raised KRW 50,000 mn, will support these initiatives by facilitating research and development as well as marketing efforts to penetrate these emerging markets.
Current Investors
Atinum Investment, Korea Investment Partners, ANDA Asset Management
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Monitoring Equipment
Website
www.i-sens.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
i-SENS - timeline of key events
i-SENS - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 52,198,326,996 | 66,549,429,796 | 82,862,589,502 | 95,608,058,129 | 101,920,703,199 | 132,468,196,930 | 156,963,800,842 | 172,996,578,932 | 189,844,257,361 | 203,707,640,796 | 232,934,791,026 | 264,837,131,105 | - | - | - |
| % Revenue Growth (YoY) | - | 27.5% | 24.5% | 15.4% | 6.6% | 30.0% | 18.5% | 10.2% | 9.7% | 7.3% | 14.3% | 13.7% | - | - | - |
| EBITDA (USD) | 13,019,661,782 | 7,936,168,689 | 18,556,889,180 | 24,951,292,287 | 26,926,927,690 | 31,527,961,636 | 30,008,740,475 | 34,953,685,000 | 40,188,915,156 | 41,374,305,440 | 45,721,149,603 | 31,860,599,920 | - | - | - |
| Operating Income (USD) | 9,136,740,782 | 7,936,168,689 | 18,556,889,180 | 18,123,677,287 | 19,412,456,690 | 25,698,026,636 | 22,756,027,475 | 27,401,714,000 | 30,172,842,156 | 30,455,987,440 | 34,826,754,603 | 19,807,041,920 | - | - | - |
| Operating Margin | 17.5% | 11.9% | 22.4% | 19.0% | 19.0% | 19.4% | 14.5% | 15.8% | 15.9% | 15.0% | 15.0% | 7.5% | - | - | - |
| % EBITDA Margin | 24.9% | 11.9% | 22.4% | 26.1% | 26.4% | 23.8% | 19.1% | 20.2% | 21.2% | 20.3% | 19.6% | 12.0% | - | - | - |
| NET Income (USD) | 7,600,638,616 | 8,744,728,272 | 18,641,927,495 | 14,339,779,381 | 14,455,365,579 | 17,544,912,414 | 15,144,223,380 | 22,414,154,718 | 23,263,932,301 | 27,295,506,466 | 25,150,572,055 | 15,907,551,228 | - | - | - |
| % Net Margin | 14.6% | 13.1% | 22.5% | 15.0% | 14.2% | 13.2% | 9.6% | 13.0% | 12.3% | 13.4% | 10.8% | 6.0% | - | - | - |
i-SENS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | i-SENS | - |
Displaying 1 - 1 of 1
i-SENS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.